Unknown

Dataset Information

0

Combined impact of body mass index and glycemic control on the efficacy of clopidogrel-aspirin therapy in patients with minor stroke or transient ischemic attack.


ABSTRACT: BACKGROUND:A single index of body mass index (BMI) may not fully address its impact on anti-platelet therapy. We aimed to elucidate the combined impact of BMI and dysglycemia expressed by glycated albumin (GA) on efficacy of clopidogrel-aspirin therapy among minor stroke (MS) or transient ischemic attack (TIA) patients. RESULTS:Patients with overweight/obesity and low GA levels still benefited from clopidogrel-aspirin therapy for stroke recurrence (Hazard ratio [HR]: 0.48, 95 % confidence interval [CI]: 0.28-0.82), so did those with high GA levels but low/normal weight (HR: 0.67, 95 % CI: 0.45-0.99). However, patients with both overweight/obesity and high GA levels did not benefit from clopidogrel-aspirin therapy (HR: 0.89, 95 % CI: 0.59-1.33). CONCLUSIONS:Compared with aspirin alone, efficacy of clopidogrel-aspirin therapy for stroke still exists in overweight/obesity patients with normal glycemic control. METHODS:In Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events trial, 3044 patients with available baseline GA were recruited. Low/normal weight and overweight/obesity were defined as BMI < 25 kg/m2 and ? 25 kg/m2, respectively. Elevated and low GA levels were defined as GA levels > 15.5 % and ? 15.5 %, respectively. The primary outcome was stroke recurrence during the 90-day follow-up.

SUBMITTER: Chen Z 

PROVIDER: S-EPMC7343455 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Combined impact of body mass index and glycemic control on the efficacy of clopidogrel-aspirin therapy in patients with minor stroke or transient ischemic attack.

Chen Zimo Z   Mo Jinglin J   Xu Jie J   Wang Anxin A   Qin Haiqiang H   Zheng Huaguang H   Liu Liping L   Meng Xia X   Li Hao H   Wang Yongjun Y  

Aging 20200616 12


<h4>Background</h4>A single index of body mass index (BMI) may not fully address its impact on anti-platelet therapy. We aimed to elucidate the combined impact of BMI and dysglycemia expressed by glycated albumin (GA) on efficacy of clopidogrel-aspirin therapy among minor stroke (MS) or transient ischemic attack (TIA) patients.<h4>Results</h4>Patients with overweight/obesity and low GA levels still benefited from clopidogrel-aspirin therapy for stroke recurrence (Hazard ratio [HR]: 0.48, 95 % co  ...[more]

Similar Datasets

| S-EPMC4943275 | biostudies-literature
| S-EPMC7457746 | biostudies-literature
| S-EPMC8081237 | biostudies-literature
| S-EPMC10424353 | biostudies-literature
| S-EPMC10446134 | biostudies-literature
| S-EPMC6298178 | biostudies-literature
| S-EPMC6583063 | biostudies-literature
| S-EPMC4901037 | biostudies-other
| S-EPMC6704730 | biostudies-literature
| S-EPMC9325246 | biostudies-literature